- The share of the clinical-stage biotech Annovis Bio ( NYSE: ANVS ) added ~7% on low volume in the pre-market trading Wednesday after the company announced the dosing of the first patient in its Phase 3 clinical trial for lead asset buntanetap in early Parkinson's Disease (PD).
- The randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of the oral therapy in 450 early PD patients who will receive 10mg buntanetap, 20mg buntanetap, or a placebo in addition to six months of the standard of care.
- Noting the official launch of the study, Chief Executive of ANVS Maria L. Maccecchini said: "With a longer treatment duration and a dose range shown to be efficacious in early studies, we are one step closer to delivering a solution that can transform the lives of patients with Parkinson's Disease.”
-
The start of the late-stage PD trial for buntanetap comes weeks after the company announced the FDA clearance for the study.
For further details see:
Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate